Skip to main content
Top
Published in: Calcified Tissue International 5/2006

01-05-2006 | Clinical Investigations

Loss of Ubiquitin Binding Is a Unifying Mechanism by Which Mutations of SQSTM1 Cause Paget’s Disease of Bone

Authors: J. R. Cavey, S. H. Ralston, P. W. Sheppard, B. Ciani, T. R. A. Gallagher, J. E. Long, M. S. Searle, R. Layfield

Published in: Calcified Tissue International | Issue 5/2006

Login to get access

Abstract

Ubiquitin-associated (UBA) domain mutations of SQSTM1 are an important cause of Paget’s disease of bone (PDB), which is a human skeletal disorder characterized by abnormal bone turnover. We previously showed that, when introduced into the full-length SQSTM1 protein, the disease-causing P392L, M404V, G411S, and G425R missense mutations and the E396X truncating mutation (representative of all of the SQSTM1 truncating mutations) cause a generalized loss of monoubiquitin binding and impaired K48-linked polyubiquitin binding at physiological temperature. Here, we show that the remaining three known PDB missense mutations, P387L, S399P, and M404T, have similar deleterious effects on monoubiquitin binding and K48-linked polyubiquitin binding by SQSTM1. The P387L mutation affects an apparently unstructured region at the N terminus of the UBA domain, some five residues from the start of the first helix, which is dispensable for polyubiquitin binding by the isolated UBA domain. Our findings support the proposal that the disease mechanism in PDB with SQSTM1 mutations involves a common loss of ubiquitin binding function of SQSTM1 and implicate a sequence extrinsic to the compact globular region of the UBA domain as a critical determinant of ubiquitin recognition by the full-length SQSTM1 protein.
Literature
1.
go back to reference Cody JD, Singer FR, Roodman GD, et al. (1997) Genetic linkage of Paget disease of the bone to chromosome 18q. Am J Hum Genet 61:1117–1122CrossRefPubMed Cody JD, Singer FR, Roodman GD, et al. (1997) Genetic linkage of Paget disease of the bone to chromosome 18q. Am J Hum Genet 61:1117–1122CrossRefPubMed
2.
go back to reference Good DA, Busfield F, Fletcher BH, et al. (2001) Linkage of Paget disease of bone to a novel region on human chromosome 18q23. Am J Hum Genet 70:517–525CrossRefPubMed Good DA, Busfield F, Fletcher BH, et al. (2001) Linkage of Paget disease of bone to a novel region on human chromosome 18q23. Am J Hum Genet 70:517–525CrossRefPubMed
3.
go back to reference Haslam SI, Van Hul W, Morales-Piga A, et al. (1998) Paget’s disease of bone: evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity. J Bone Miner Res 13:911–917CrossRefPubMed Haslam SI, Van Hul W, Morales-Piga A, et al. (1998) Paget’s disease of bone: evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity. J Bone Miner Res 13:911–917CrossRefPubMed
4.
go back to reference Hocking LJ, Herbert CA, Nicholls RK, et al. (2001) Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. Am J Hum Genet 69:1055–1061CrossRefPubMed Hocking LJ, Herbert CA, Nicholls RK, et al. (2001) Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. Am J Hum Genet 69:1055–1061CrossRefPubMed
5.
go back to reference Hughes AE, Shearman AM, Weber JL, et al. (1994) Genetic linkage of familial expansile osteolysis to chromosome 18q. Hum Mol Genet 3:359–361PubMed Hughes AE, Shearman AM, Weber JL, et al. (1994) Genetic linkage of familial expansile osteolysis to chromosome 18q. Hum Mol Genet 3:359–361PubMed
6.
go back to reference Laurin N, Brown JP, Lemainque A, et al. (2001) Paget disease of bone: mapping of two loci at 5q35-qter and 5q31. Am J Hum Genet 69:528–543CrossRefPubMed Laurin N, Brown JP, Lemainque A, et al. (2001) Paget disease of bone: mapping of two loci at 5q35-qter and 5q31. Am J Hum Genet 69:528–543CrossRefPubMed
7.
go back to reference Eekhoff EW, Karperien M, Houtsma D, et al. (2004) Familial Paget’s disease in the Netherlands: occurrence, identification of new mutations in the sequestosome 1 gene, and their clinical associations. Arthritis Rheum 50:1650–1654CrossRefPubMed Eekhoff EW, Karperien M, Houtsma D, et al. (2004) Familial Paget’s disease in the Netherlands: occurrence, identification of new mutations in the sequestosome 1 gene, and their clinical associations. Arthritis Rheum 50:1650–1654CrossRefPubMed
8.
go back to reference Falchetti A, Di Stefano M, Marini F, et al. (2004) Two novel mutations at exon 8 of Sequestosome 1 gene (SQSTM1) in an Italian serie of patients affected by Paget’s disease of bone (PDB). J Bone Miner Res 19:1013–1017CrossRefPubMed Falchetti A, Di Stefano M, Marini F, et al. (2004) Two novel mutations at exon 8 of Sequestosome 1 gene (SQSTM1) in an Italian serie of patients affected by Paget’s disease of bone (PDB). J Bone Miner Res 19:1013–1017CrossRefPubMed
9.
go back to reference Hocking LJ, Lucas GJA, Daroszewska A, et al. (2002) Domain specific mutations in Sequestosome 1 (SQSTM1) cause familial and sporadic Paget’s disease. Hum Mol Genet 11:2735–2739CrossRefPubMed Hocking LJ, Lucas GJA, Daroszewska A, et al. (2002) Domain specific mutations in Sequestosome 1 (SQSTM1) cause familial and sporadic Paget’s disease. Hum Mol Genet 11:2735–2739CrossRefPubMed
10.
go back to reference Hocking LJ, Lucas GJA, Daroszewska A, et al. (2004) Novel UBA domain mutations of SQSTM1 in Paget’s disease of bone: genotype phenotype correlation, functional analysis, and structural consequences. J Bone Miner Res 19:1122–1127CrossRefPubMed Hocking LJ, Lucas GJA, Daroszewska A, et al. (2004) Novel UBA domain mutations of SQSTM1 in Paget’s disease of bone: genotype phenotype correlation, functional analysis, and structural consequences. J Bone Miner Res 19:1122–1127CrossRefPubMed
11.
go back to reference Johnson-Pais TL, Wisdom JH, Weldon KS, et al. (2003) Three novel mutations in SQSTM1 identified in familial Paget’s disease of bone. J Bone Miner Res 18:1748–1753CrossRefPubMed Johnson-Pais TL, Wisdom JH, Weldon KS, et al. (2003) Three novel mutations in SQSTM1 identified in familial Paget’s disease of bone. J Bone Miner Res 18:1748–1753CrossRefPubMed
12.
go back to reference Laurin N, Brown JP, Morissette J, Raymond V (2002) Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 70:1582–1588CrossRefPubMed Laurin N, Brown JP, Morissette J, Raymond V (2002) Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 70:1582–1588CrossRefPubMed
13.
go back to reference Duran A, Serrano M, Leitges M, et al. (2004) The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell 6:303–309CrossRefPubMed Duran A, Serrano M, Leitges M, et al. (2004) The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell 6:303–309CrossRefPubMed
14.
go back to reference Raasi S, Orlov I, Fleming KG, Pickart CM (2004) Binding of polyubiquitin chains to ubiquitin-associated (UBA) domains of HHR23A. J Mol Biol 341:1367–1379CrossRefPubMed Raasi S, Orlov I, Fleming KG, Pickart CM (2004) Binding of polyubiquitin chains to ubiquitin-associated (UBA) domains of HHR23A. J Mol Biol 341:1367–1379CrossRefPubMed
15.
go back to reference Wilkinson CR, Seeger M, Hartmann-Petersen R, et al. (2001) Proteins containing the UBA domain are able to bind to multi-ubiquitin chains. Nat Cell Biol 3:939–943CrossRefPubMed Wilkinson CR, Seeger M, Hartmann-Petersen R, et al. (2001) Proteins containing the UBA domain are able to bind to multi-ubiquitin chains. Nat Cell Biol 3:939–943CrossRefPubMed
16.
go back to reference Ciani B, Layfield R, Cavey JR, Sheppard PW, Searle MS (2003) Structure of the UBA domain of p62 (SQSTM1) and implications for mutations which cause Paget’s disease of bone. J Biol Chem 278:37409–37412CrossRefPubMed Ciani B, Layfield R, Cavey JR, Sheppard PW, Searle MS (2003) Structure of the UBA domain of p62 (SQSTM1) and implications for mutations which cause Paget’s disease of bone. J Biol Chem 278:37409–37412CrossRefPubMed
17.
go back to reference Shin J (1998) p62 and the sequestosome, a novel mechanism for protein metabolism. Arch Pharm Res 21:629–633PubMedCrossRef Shin J (1998) p62 and the sequestosome, a novel mechanism for protein metabolism. Arch Pharm Res 21:629–633PubMedCrossRef
18.
go back to reference Vadlamudi RK, Joung I, Strominger JL, Shin J (1996) p62, a phosphotyrosine-independent ligand of the SH2 domain of p56lck, belongs to a new class of ubiquitin-binding proteins. J Biol Chem 271:20235–20237CrossRefPubMed Vadlamudi RK, Joung I, Strominger JL, Shin J (1996) p62, a phosphotyrosine-independent ligand of the SH2 domain of p56lck, belongs to a new class of ubiquitin-binding proteins. J Biol Chem 271:20235–20237CrossRefPubMed
19.
go back to reference Kanayama A, Seth RB, Sun L, et al. (2004) TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol Cell 15:535–548CrossRefPubMed Kanayama A, Seth RB, Sun L, et al. (2004) TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol Cell 15:535–548CrossRefPubMed
20.
21.
go back to reference Wooten MW, Geetha T, Seibenhener ML, et al. (2005) The p62 scaffold regulates NGF-induced NF-kappa B activation by influencing TRAF6 polyubiquitination. J Biol Chem 280:35625–35629CrossRefPubMed Wooten MW, Geetha T, Seibenhener ML, et al. (2005) The p62 scaffold regulates NGF-induced NF-kappa B activation by influencing TRAF6 polyubiquitination. J Biol Chem 280:35625–35629CrossRefPubMed
22.
go back to reference Cavey JR, Ralston SH, Hocking LJ, et al. (2005) Loss of ubiquitin-binding associated with Paget’s disease of bone p62 (SQSTM1) mutations. J Bone Miner Res 20:619–624CrossRefPubMed Cavey JR, Ralston SH, Hocking LJ, et al. (2005) Loss of ubiquitin-binding associated with Paget’s disease of bone p62 (SQSTM1) mutations. J Bone Miner Res 20:619–624CrossRefPubMed
23.
go back to reference Thrower JS, Hoffman L, Rechsteiner M, Pickart CM (2000) Recognition of the polyubiquitin proteolytic signal. EMBO J 19:94–102CrossRefPubMed Thrower JS, Hoffman L, Rechsteiner M, Pickart CM (2000) Recognition of the polyubiquitin proteolytic signal. EMBO J 19:94–102CrossRefPubMed
24.
go back to reference Mueller TD, Feigon J (2002) Solution structures of UBA domains reveal a conserved hydrophobic surface for protein-protein interactions. J Mol Biol 319:1243–1255CrossRefPubMed Mueller TD, Feigon J (2002) Solution structures of UBA domains reveal a conserved hydrophobic surface for protein-protein interactions. J Mol Biol 319:1243–1255CrossRefPubMed
25.
go back to reference Teitelbaum SL, Ross FP (2003) Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638–649CrossRefPubMed Teitelbaum SL, Ross FP (2003) Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638–649CrossRefPubMed
26.
go back to reference Babu JR, Geetha T, Wooten MW (2005) Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J Neurochem 94:192–203CrossRefPubMed Babu JR, Geetha T, Wooten MW (2005) Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J Neurochem 94:192–203CrossRefPubMed
27.
go back to reference Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR, Wooten MW (2004) Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol 24:8055–8068CrossRefPubMed Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR, Wooten MW (2004) Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol 24:8055–8068CrossRefPubMed
28.
go back to reference Raasi S, Varadan R, Fushman D, Pickart CM (2005) Diverse polyubiquitin interaction properties of ubiquitin-associated domains. Nat Struct Mol Biol 12:708–714CrossRefPubMed Raasi S, Varadan R, Fushman D, Pickart CM (2005) Diverse polyubiquitin interaction properties of ubiquitin-associated domains. Nat Struct Mol Biol 12:708–714CrossRefPubMed
29.
go back to reference Raasi S, Pickart CM (2003) Rad23 ubiquitin-associated domains (UBA) inhibit 26 S proteasome-catalyzed proteolysis by sequestering lysine 48-linked polyubiquitin chains. J Biol Chem 278:8951–8959CrossRefPubMed Raasi S, Pickart CM (2003) Rad23 ubiquitin-associated domains (UBA) inhibit 26 S proteasome-catalyzed proteolysis by sequestering lysine 48-linked polyubiquitin chains. J Biol Chem 278:8951–8959CrossRefPubMed
30.
go back to reference Walters KJ, Lech PJ, Goh AM, Wang Q, Howley PM (2003) DNA-repair protein hHR23a alters its protein structure upon binding proteasomal subunit S5a. Proc Natl Acad Sci USA 100:12694–12699CrossRefPubMed Walters KJ, Lech PJ, Goh AM, Wang Q, Howley PM (2003) DNA-repair protein hHR23a alters its protein structure upon binding proteasomal subunit S5a. Proc Natl Acad Sci USA 100:12694–12699CrossRefPubMed
31.
go back to reference Merkley N, Shaw GS (2004) Solution structure of the flexible class II ubiquitin-conjugating enzyme Ubc1 provides insights for polyubiquitin chain assembly. J Biol Chem 279:47139–47147CrossRefPubMed Merkley N, Shaw GS (2004) Solution structure of the flexible class II ubiquitin-conjugating enzyme Ubc1 provides insights for polyubiquitin chain assembly. J Biol Chem 279:47139–47147CrossRefPubMed
Metadata
Title
Loss of Ubiquitin Binding Is a Unifying Mechanism by Which Mutations of SQSTM1 Cause Paget’s Disease of Bone
Authors
J. R. Cavey
S. H. Ralston
P. W. Sheppard
B. Ciani
T. R. A. Gallagher
J. E. Long
M. S. Searle
R. Layfield
Publication date
01-05-2006
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 5/2006
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-005-1299-6

Other articles of this Issue 5/2006

Calcified Tissue International 5/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine